

PP01

What's Up With icSDRG? Navigating Through an Example

Bidhya Sagar Basnet, Roche-Genentech (basnet.bidhya@gene.com), Srinivas Kovvuri (srinivas.kovvuri@adctherapeutics.com), Randi McFarland (randi.mcfarland@ephicacy.com), Christine McNichol (christine.mcnichol@fortrea.com), Kiran Kundarapu (kiran.kundarapu@lilly.com)

Abstract

The Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) are essential for the approval of New Drug Applications (NDAs) and Biologics License Applications (BLAs). Applicants must submit data supporting these integrated analyses along with a Reviewer’s Guide. One strategy out of multiple ways in creating integrated data is integrating study-level data based on the Study Data Tabulation Model (CDISC SDTM) to build integrated analysis datasets. To facilitate this, the PHUSE Optimizing the Use of Data Standards (ODS) Working Group (WG) has developed a completion guidance template for the integrated clinical Study Data Reviewer’s Guide (icSDRG), which was shared at PHUSE CSS 2024. We also created an example document to clarify regulatory agencies' (RA) requirements and ensure consistent data submissions across the industry. This poster illustrates an example of the icSDRG, discusses key pooling strategies, and offers guidance on preparing integrated SDTM data for RA submission.

cSDRG vs icSDRG – What’s new?

cSDRG vs icSDRG

Source data

*SDTM no longer supported per the Data Standards Catalog

Introduction

1.4 Source Data Used for Integrated Study Dataset Creation

STUDYID	Protocol Number	Source Data Standard	Cutoff Date or DBL Date / Study Status
QRS01	PRN-1001	SDTM 1.2/IG 3.1.1 SDTM Controlled Terminology 2016-03-25	01Jan2018/Completed
QRS02	PRN-2001	SDTM 2.0/IG 3.4 SDTM Controlled Terminology 2021-06-25	01Jul2024/Ongoing
QRS03	PRN-3001	SDTM 1.7/IG 3.3 SDTM Controlled Terminology 2019-06-28	01Jan2021/Completed

Additional Content of Interest

Filename Submitted	Description of Use	Define-XML Reference
specchar.xlsx	Special Characters Dictionary	Special_char.xlsx
tsitecds.xpt	Reference file for subjects that transitioned sites during study conduct	Trans_Site_Codes_10Jan2023.csv
nstdump.xlsx	Unit Mapping for Non-Standard Original Units	Unit-Mapping_v3.xlsx

1.5 Traceability Flow Diagram

*SDTM no longer supported per the Data Standard Catalog

Protocol Numbers and Titles

2.1 Protocol Numbers and Titles

Protocol Number	Indication(s)/Protocol Title	Phase
PRN-1001	Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of DRUG A in Subjects with Moderate to Severe Ulcerative Colitis	II
PRN-2001	Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of DRUG A in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis	III
PRN-3001	Phase 3, Multicenter, Open-Label Extension Trial of DRUG A as Therapy for Moderate to Severe Ulcerative Colitis	III

Two additional subsections under introduction that are not in cSDRG:

- Source Data Used for Integrated Study Dataset Creation

- Traceability Flow Diagram showing the integrated SDTM dataset

This subsection provides information about the protocol numbers, title, and the phase of the studies that are included in the integrated SDTM dataset

Considerations Related to Creation of Integrated Datasets

3.1 Overview

Are Trial Design datasets included in the submission? **NO**
e.g., Trial design datasets are available in the study-level datasets.

Do the integrated SDTM datasets include all the domains from the individual studies? **NO**
e.g., PK was excluded from this integration because it will not be used in the analyses.

Are split datasets included? **YES**

Dataset name	Description
QS1	Contains QSCAT = "PASI", "Ulcerative Colitis Stool Diary"
QS2	Contains all other QSCAT categories

3.2 Treatment Variables

Do the integrated SDTM datasets include subjects with unplanned treatment? **YES**
Two participants received unplanned treatment in Study QRS02. One received treatment A, but in week 4, they were given the wrong kit, so they took treatment B.

Are the treatment variable values harmonized? **YES**

If yes, describe the harmonization:

STUDYID	TREATMENT ARM	HARMONIZED ARM
QRS01	Drug A1 + pre-med	Drug A
QRS01	Drug B	Drug B
QRS02	Drug A	Drug A
QRS03	Drug A2	Drug A

3.3 Considerations that Require Special Integration Rules

Were any additional updates (e.g., codelists, value-level metadata, dictionaries) performed when integrating? **YES**

- Text values have been converted to uppercase for consistency as needed across datasets.
- Standard units have been harmonized across studies.
- Terminology was harmonized as documented in Section 1.3.
- Studies QRS01 and QRS03 were upversioned to the latest MedDRA version, as found in Section 1.3.

STUDYID	Dataset	Variable	Conditional Variable	Conditional Value	Original Value	Harmonized Value
QRS01, QRS03	LB	LBCAT	LBTESTCD	HDL	LIPIDS	CHEMISTRY
QRS01, QRS03	LB	LBCAT			BLOOD_CHEMISTRY	CHEMISTRY
QRS02	SUPPAE	QVAL	QNAM	AERELCM	yes	Y
QRS02	LB	LBTEST	LBTESTCD	LBALL	Labs Data	Laboratory Test Results Data

3.4 Inclusion of Visits and Records

Were unscheduled visits incorporated in any integrated study datasets? **Yes**

Are all records included from each study for the integrated datasets? **Yes**

This section is to:

- Provide an overview of integrated SDTM datasets
- List all integrated datasets included in a submission
- Identify each dataset’s purpose
- Indicate split datasets

This section describes:

- Trial Design datasets, whether they are included in the submission
- Split datasets if applicable
- Adjudication of data and mapping details
- Treatment harmonization rules
- Any special rules applied in integration
- Whether all visits, including unscheduled, from each study are included in the integrated SDTM dataset

Integrated SDTM Domains

4.1 Integrated SDTM Domains

Dataset – Dataset Label	Efficacy (E)/ Safety (S)/ Immunogenicity (I)	Other	Custom	Split Datasets	SUPP.	Related Using RELREC	All Studies Contribute (X=Yes)
AE – Adverse Events	S			X		DS, CM	X
APMH – Associated Persons Medical History		X					
CM – Concomitant Medications	S			X		AE	X
DM – Demographics		X		X			X
DS – Disposition		X				AE	X
QS - Questionnaire	E		X				X

Submission of Programs

Submission of Programs is the new optional subsection that has been introduced in icSDRG, considering a need to submit an integrated SDTM program in certain circumstances with the following default text: “Integrated SDTM dataset programs are not submitted, but available upon request”

6. Submission of Programs

Integrated SDTM dataset programs are not submitted, but available upon request.

6.1 Integrated SDTM Programs

Program Name	Dataset	Macro Used
Not Applicable		

6.2 Macro Programs

Program Name	Purpose
Not Applicable	

Disclaimer: All views expressed in this paper are those of the authors and are not necessarily those of PHUSE, CDISC, regulatory agencies, or the author’s companies: Roche-Genentech, ADC Therapeutics, Efficacy Consulting Services, Fortrea, and Lilly.